Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol - GW Pharmaceuticals

Drug Profile

Cannabidiol - GW Pharmaceuticals

Alternative Names: CBD - GW Pharmaceuticals; Epidiolex; Epidyolex; GW-42003; GWP-42003; GWP-42003-P

Latest Information Update: 25 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GW Pharmaceuticals
  • Developer GW Pharmaceuticals; University of Alabama at Birmingham; University of Utah
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Serotonin 1 receptor modulators; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome; Cerebral ischaemia; Infantile spasms; Tuberous sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dravet syndrome; Lennox-Gastaut syndrome; Tuberous sclerosis
  • Phase III Epilepsy; Infantile spasms; Rett syndrome
  • Phase II Heroin-related disorders; Opioid-related disorders; Parkinson's disease; Pervasive child development disorders; Schizophrenia
  • Phase I Cerebral ischaemia
  • No development reported Duchenne muscular dystrophy; Ovarian cancer
  • Discontinued Dyslipidaemias; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 17 May 2021 GW Pharmaceuticals initiates an expanded-access programme for Epielpsy (Treatment resistant) before April 2021
  • 05 May 2021 Launched for Tuberous sclerosis (In children, In adolescents, In adults, In infants) in United Kingdom (PO) by May 2021
  • 05 May 2021 Launched for Tuberous sclerosis in Germany (In children, In adolescents, In adults, In infants) (PO) by May 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top